Chugai’s HEMLIBRA® Receives Priority Review Status from U.S. FDA for Hemophilia A Without Inhibitors
Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that the U.S. Food and Drugs Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) and granted Priority Review for HEMLIBRA® [US generic name: emicizumab-kxwh] for adults and children with hemophilia A without factor VIII inhibitors. The FDA is expected to make a decision on approval by 4 October, 2018. In the US, Genentech, Inc., a member of Roche Group is the BLA holder and is engaged in the development and distribution of HEMLIBRA, which was approved and launched for hemophilia A with inhibitors in November 2017.
“We are very proud that HEMLIBRA has been granted a second Priority Review for hemophilia A without inhibitors following the previous designation for hemophilia A with inhibitors, which underscores the innovation of this drug,” said Chugai’s Executive Vice President, Co-Head of Project & Lifecycle Management Unit, Dr. Yasushi Ito. “In treatment of hemophilia A without inhibitors, there still remain unmet medical needs in the management of bleeding. Given this Priority Review status, we hope to be able to contribute to people with hemophilia A and their caregivers as soon as possible by providing HEMLIBRA as a new treatment option that can be administered subcutaneously with good bleeding control and eased treatment burden.”
The sBLA filing and Priority Review are based on the results of HAVEN 3 study (NCT02847637), which has been conducted with adults and adolescents with hemophilia A without factor VIII inhibitors under a collaboration between Chugai, Roche and Genentech. In EU, Roche has already filed the results to the European Medicines Agency for a supplemental indication of hemophilia A without inhibitors.
Priority Review designation is granted to medicines that the FDA has determined to have the potential to provide significant improvements in safety or effectiveness of the treatment, prevention or diagnosis of a serious disease. In Japan, HEMLIBRA received regulatory approval in March 2018 for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with congenital factor VIII deficiency (hemophilia A) with factor VIII inhibitors and, in April 2018, was filed to the Ministry of Health, Labour and Welfare for a supplemental indication of hemophilia A without inhibitors.
Trademarks used or mentioned in this release are protected by law.
Chugai Pharmaceutical is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs, mainly focusing on the oncology area.
In Japan, Chugai’s research facilities in Gotemba and Kamakura are collaborating to develop new pharmaceuticals and laboratories in Ukima are conducting research for technology development for industrial production. Overseas, Chugai Pharmabody Research based in Singapore is engaged in research focusing on the generation of novel antibody drugs by utilizing Chugai’s proprietary innovative antibody engineering technologies. Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development activities in the United States and Europe.
The consolidated revenue in 2017 of Chugai totaled 534.2 billion yen and the operating income was 103.2 billion yen (IFRS Core basis).
Additional information is available on the internet at https://www.chugai-pharm.co.jp/english.
Chugai Pharmaceutical Co., Ltd.
Media Relations Group, Corporate Communications Dept.,
For US media
Chugai Pharma USA Inc.
For European media
Chugai Pharma France SAS
For Taiwanese media
Chugai Pharma Taiwan Ltd.
Chugai Pharmaceutical Co., Ltd.
Investor Relations Group, Corporate Communications Dept.,
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Scanlog Strengthens its Position at the Cutting Edge of Logistics Innovation by Embracing Robotic Process Automation from Softomotive15.10.2018 12:08 | Pressemelding
Scandinavian Logistics Partners AB (Scanlog), a rapidly expanding Scandinavian logistics company specializing in international transports, is using ProcessRobot from Softomotive to help transform its order booking process and develop a smarter workflow. ProcessRobot is a leading enterprise Robotic Process Automation (RPA) platform, including enterprise grade security and controls, with links to best-of-breed AI technologies. With ProcessRobot handling increasing numbers of customer orders, Scanlog has fortified its position as a technology leader in the logistics sector, and can deliver a speedier shipping service for its clients. Mattias Ljungberg , CEO of Scanlog, explains: “With ProcessRobot, we have reduced the time it takes to process each customer order by 89 percent. Previously it took a human employee up to four minutes to enter the booking details to our systems: now, the robot completes the task within 20 seconds.” Scanlog has ambitious plans to automate many other processes
MAXON Announces Senior Leadership Appointments15.10.2018 12:00 | Pressemelding
MAXON, the leading developer of professional 3D software solutions, today announced leadership appointments to make it a globally-focused software development company. The executive leadership team changes, effective immediately, reflect the strategic goals of David McGavran, Chief Executive Officer, for the future of MAXON and its acclaimed 3D software application, Cinema 4D. “This is an exciting and transformational time in the evolution of MAXON and I’m eager to work with our new leadership team that represents the very best talent across our offices poised to take MAXON to the next level,” stated McGavran. “With proven track records of delivering strong results, I am pleased to have these talented and passionate executives join me in streamlining operational initiatives to best serve global customers and partners, anticipate the ever-changing needs of the 3D digital landscape, and maintain Cinema 4D’s standing as a best-in-class market leader in 3D content creation.” Executive Team
PotNetwork Holdings, Inc. Files Form 10 To Become SEC Reporting Company15.10.2018 12:00 | Pressemelding
PotNetwork Holdings, Inc. (OTC Pink: POTN) announced today that it has filed a Registration Statement on Form 10 with the U.S. Securities and Exchange Commission (SEC) to register its common stock under the Securities Exchange Act of 1934, as amended (the Act) including its audited financial statements for the year ended December 31, 2017 and unaudited interim financial statements through June 30, 2018. POTN had engaged PCAOB member firm Manohar, Chowdhry & Associates, in July 2017 to replace its former auditor. The Company’s voluntary filing of the Form 10 will make the Company subject to the periodic reporting requirements of the Act which includes annual, quarterly and current report filings. Additionally, the filing will enable the Company’s management to move forward with its application to OTC Markets to uplist to the OTCQB market tier. As a result of investor feedback and management’s plan for a new, broadened strategic direction, the Company has rescinded the previously announc
Scientist.com’s Online Compliance Solution (COMPLi™) Wins Prestigious CPhl Pharma Award15.10.2018 11:55 | Pressemelding
Scientist.com is pleased to announce its online compliance solution COMPLi™ was recognized as the winner of the prestigious Regulatory Procedures and Compliance award at the 2018 CPhl Pharma Awards held in Madrid, Spain on October 9, 2018. COMPLi™ is a first-of-its-kind solution that allows pharmaceutical and biotech companies to confidently outsource regulated services such as human biological sample (HBS) acquisition, secondary real-world evidence (RWE), health economics and outcomes research (HEOR) and GxP services. “COMPLi™ enables research organizations to address the biggest challenges they face when sourcing regulated services: transparency, visibility and control,” stated Matt McLoughlin, VP of Compliance at Scientist.com. “COMPLi™ addresses compliance and governance requirements at every critical step of the sourcing process to speed up drug research and reduce the associated risks of outsourcing.” By simplifying and standardizing processes that previously took months, COMPLi™
DEWA Organises 20th WETEX & 3rd Dubai Solar Show from 23-25 October 201815.10.2018 10:58 | Pressemelding
In a press conference held in Dubai, HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA), announced details of the 20th Water, Energy, Technology, and Environment Exhibition (WETEX 2018) and the 3rd Dubai Solar Show. DEWA organises the two exhibitions at the Dubai International Convention and Exhibition Centre from 23 to 25 October 2018. WETEX 2018, under the theme ‘At the forefront of sustainability,’ will be the biggest in the exhibition’s history, covering 78,413 square metres. It will host 2,100 exhibitors from 53 countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181015005457/en/ DEWA organises 20th WETEX & 3rd Dubai Solar Show from 23-25 October 2018 (Photo: AETOSWire) WETEX is the largest of its kind in the region and one of the biggest specialised exhibitions in the world. It has become an annual event for regional and international companies in the energy, water, clean energy,
Bank of America Reports Third-Quarter 2018 Financial Results15.10.2018 10:54 | Pressemelding
Bank of America reported its third-quarter 2018 financial results today. The news release, supplemental filing and investor presentation can be accessed in the following ways: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181015005455/en/ Bank of America newsroom at https://newsroom.bankofamerica.com Bank of America Investor Relations website at http://investor.bankofamerica.com Business Wire’s news webpage at http://www.businesswire.com/portal/site/home/news Investor Conference Call information Chief Executive Officer Brian Moynihan and Chief Financial Officer Paul Donofrio will discuss the financial results in a conference call at 8:30 a.m. ET today. For a listen-only connection to the conference call, dial 1.877.200.4456 (U.S.) or 1.785.424.1732 (international), and the conference ID is 79795. Please dial in 10 minutes prior to the start of the call. Investors can also listen to a live audio webcast of the conference cal